Enzymatica signs distribution agreement with Tamro for the Finnish market
Enzymatica has signed a distribution agreement with Tamro to sell the common cold product ColdZyme® Mouth spray in Finland. Effective today the agreement provides Tamro with exclusive rights to sell, market and distribute ColdZyme to all Finnish pharmacies.
The launch in Finland will take place in conjunction with the annual pharmacy fair in Helsinki on November 13-15, 2015. The agreement covers the products ColdZyme 20 ml and ColdZyme One Cold, 7 ml.
"This expansion is part of our strategy to reach outside of Scandinavia through partners responsible for the entire supply chain, including the costs of marketing. Tamro is part of Phoenix Group, which is Europe's largest distributor of pharmaceutical products, and is a perfect partner for the sale of non-prescription products in Finland ", says Fredrik Lindberg, CEO of Enzymatica.
In total there are about 800 pharmacies in Finland with many drugstore branches. Enzymatica estimates that the total value of the non-prescription cold and flu market in Finnish pharmacies amounts to about SEK 375 million.
"Tamro is really excited to work with Enzymatica. Through collaboration we have good chances to get ColdZyme to succeed in the Finnish market", says Kai Kaasalainen, CEO of Tamro.
Through the agreement Enzymatica strengthens its presence in the Nordic countries and enables more consumers to avoid getting a cold. ColdZyme is currently sold directly by Enzymatica in Sweden, Norway and Denmark and through a contract organization in the UK. The products are registered as medical devices at the Swedish Medical Products Agency, allowing marketing and sales in Sweden and other countries within the EEA.
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: email@example.com
Eric Korpi, Head of Category Management, Tamro
Tel: +358 40 836 0527 | E-post: firstname.lastname@example.org
About Enzymatica AB
Enzymatica is a life science company whose business concept is to offer effective help against some of our most common diseases where viruses or bacteria play a decisive role. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on four markets. The product became the leading article for colds in Swedish pharmacies in winter 2014-2015. Development includes medical devices in upper respiratory infections and oral health, and veterinary products. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.
Erik Penser Bankaktiebolag is Certified Adviser for Enzymatica.
For more information, please visit: www.tamro.fi/en